Veracyte (VCYT) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

VCYT Stock Forecast

Veracyte stock forecast is as follows: an average price target of $35.00 (represents a -2.62% downside from VCYT’s last price of $35.94) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

VCYT Price Target

The average price target for Veracyte (VCYT) is $35.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $44.00 to $26.00. This represents a potential -2.62% downside from VCYT's last price of $35.94.

VCYT Analyst Ratings

Buy

According to 5 Wall Street analysts, Veracyte's rating consensus is 'Buy'. The analyst rating breakdown for VCYT stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 0 'Hold' (0.00%), 1 'Sell' (20.00%), and 0 'Strong Sell' (0.00%).

Veracyte Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 07, 2024	Mike Matson	Needham	$44.00	$35.85	22.74%	22.43%
Aug 12, 2024	Tejas Savant	Morgan Stanley	$26.00	$29.41	-11.58%	-27.66%
May 04, 2022	-	Morgan Stanley	$23.00	$21.00	9.55%	-36.00%
May 04, 2022	-	Needham	$26.00	$21.46	21.16%	-27.66%

Row per page

Go to

The latest Veracyte stock forecast, released on Nov 07, 2024 by Mike Matson from Needham, set a price target of $44.00, which represents a 22.74% increase from the stock price at the time of the forecast ($35.85), and a 22.43% increase from VCYT last price ($35.94).

Veracyte Price Target by Period

	1M	3M	12M
# Anlaysts	1	1	2
Avg Price Target	$44.00	$44.00	$35.00
Last Closing Price	$35.94	$35.94	$35.94
Upside/Downside	22.43%	22.43%	-2.62%

In the current month, the average price target of Veracyte stock is $44.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 22.43% increase as opposed to Veracyte's last price of $35.94. This month's average price target is down 0.00% compared to last quarter, and up 25.71% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 15, 2024	UBS	-	Buy	Initialise
Oct 10, 2024	Guggenheim	-	Buy	Initialise
Aug 12, 2024	Morgan Stanley	Underweight	Underweight	Hold
Aug 07, 2024	Needham	Buy	Buy	Hold
Aug 07, 2024	William Blair	Outperform	Outperform	Hold
Jan 05, 2023	Scotiabank	-	Sector Outperform	Initialise

Row per page

Go to

Veracyte's last stock rating was published by UBS on Oct 15, 2024. The company Initialise its VCYT rating from "null" to "Buy".

Veracyte Financial Forecast

Veracyte Revenue Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	$98.20M	$90.11M	$90.32M	$82.42M	$80.30M	$75.59M	$72.86M	$67.78M	$67.34M	$60.37M	$55.10M	$36.70M	$34.54M	$31.12M	$20.70M	$31.12M	$29.73M	$30.97M
Avg Forecast	$142.14M	$137.32M	$133.50M	$121.98M	$129.49M	$125.13M	$122.79M	$111.99M	$116.68M	$109.82M	$100.27M	$93.35M	$91.97M	$84.36M	$83.05M	$75.80M	$73.94M	$66.41M	$68.08M	$61.92M	$62.52M	$54.00M	$48.07M	$32.67M	$32.20M	$23.88M	$17.08M	$30.61M	$29.57M	$30.06M
High Forecast	$145.42M	$140.49M	$136.58M	$124.79M	$132.48M	$128.02M	$125.62M	$117.16M	$117.14M	$110.27M	$100.27M	$93.35M	$94.09M	$85.67M	$84.97M	$77.55M	$75.65M	$66.41M	$68.08M	$61.92M	$62.52M	$54.00M	$48.07M	$32.67M	$32.20M	$23.88M	$17.08M	$30.61M	$29.57M	$30.06M
Low Forecast	$138.44M	$133.74M	$130.02M	$118.80M	$126.12M	$121.87M	$119.59M	$107.63M	$116.22M	$109.36M	$100.27M	$93.35M	$89.57M	$83.08M	$80.89M	$73.83M	$72.02M	$66.41M	$68.08M	$61.92M	$62.52M	$54.00M	$48.07M	$32.67M	$32.20M	$23.88M	$17.08M	$30.61M	$29.57M	$30.06M
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	8	7	6	5	5
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	1.07%	1.07%	1.09%	1.09%	1.09%	1.14%	1.07%	1.09%	1.08%	1.12%	1.15%	1.12%	1.07%	1.30%	1.21%	1.02%	1.01%	1.03%

Veracyte's average Quarter revenue forecast for Mar 24 based on 1 analysts is $93.35M, with a low forecast of $93.35M, and a high forecast of $93.35M. VCYT's average Quarter revenue forecast represents a -4.93% decrease compared to the company's last Quarter revenue of $98.20M (Dec 23).

Veracyte EBITDA Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	8	7	6	5	5
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	$5.03M	-	$-1.19M	$-3.83M	$1.14M	$-3.36M	$-5.34M	$-7.75M	$-4.91M	$-9.28M	$-4.63M	$-43.06M	$2.11M	$-2.08M	$-9.00M	$-9.69M	$-6.10M	$295.00K
Avg Forecast	$-20.43M	$-19.74M	$-19.19M	$-17.53M	$-18.62M	$-17.99M	$-17.65M	$-16.10M	$-16.77M	$-15.79M	$-14.41M	$-20.42M	$-13.22M	$-12.13M	$-11.94M	$-18.56M	$-5.74M	$-7.78M	$-7.97M	$-16.87M	$-7.32M	$-6.32M	$-5.63M	$-135.64M	$-3.77M	$-2.80M	$-2.00M	$-7.75M	$-3.46M	$-3.52M
High Forecast	$-19.90M	$-19.23M	$-18.69M	$-17.08M	$-18.13M	$-17.52M	$-17.19M	$-15.47M	$-16.71M	$-15.72M	$-14.41M	$-16.33M	$-12.88M	$-11.94M	$-11.63M	$-14.85M	$-4.59M	$-7.78M	$-7.97M	$-13.50M	$-7.32M	$-6.32M	$-5.63M	$-108.51M	$-3.77M	$-2.80M	$-2.00M	$-6.20M	$-3.46M	$-3.52M
Low Forecast	$-20.90M	$-20.20M	$-19.63M	$-17.94M	$-19.04M	$-18.40M	$-18.06M	$-16.84M	$-16.84M	$-15.85M	$-14.41M	$-24.50M	$-13.53M	$-12.32M	$-12.21M	$-22.27M	$-6.89M	$-7.78M	$-7.97M	$-20.25M	$-7.32M	$-6.32M	$-5.63M	$-162.77M	$-3.77M	$-2.80M	$-2.00M	$-9.30M	$-3.46M	$-3.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-0.38%	-	0.10%	0.21%	-0.20%	0.43%	0.67%	0.46%	0.67%	1.47%	0.82%	0.32%	-0.56%	0.74%	4.50%	1.25%	1.76%	-0.08%

1 analysts predict VCYT's average Quarter EBITDA for Mar 24 to be $-20.42M, with a high of $-16.33M and a low of $-24.50M. This is -506.01% lower than Veracyte's previous annual EBITDA (Dec 23) of $5.03M.

Veracyte Net Income Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	8	7	6	5	5
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	$-28.29M	$-29.62M	$-8.40M	$-5.68M	$-3.84M	$-8.72M	$-9.53M	$-14.46M	$-10.53M	$-14.13M	$-9.04M	$-41.87M	$26.86K	$-4.12M	$-11.03M	$-11.72M	$-7.46M	$-730.00K
Avg Forecast	$22.64M	$20.10M	$19.04M	$15.36M	$15.07M	$12.63M	$11.89M	$7.46M	$9.50M	$2.55M	$-1.29M	$-20.41M	$-7.87M	$-11.49M	$-11.95M	$-18.56M	$-12.30M	$-19.93M	$-17.20M	$-16.87M	$-12.39M	$-13.12M	$-19.41M	$-131.88M	$-7.46M	$-16.20M	$-20.53M	$-9.37M	$-6.30M	$-5.66M
High Forecast	$23.32M	$20.71M	$19.61M	$15.82M	$15.52M	$13.01M	$12.24M	$12.08M	$16.28M	$2.62M	$-1.24M	$-16.33M	$2.25M	$-9.20M	$-11.55M	$-14.85M	$-9.84M	$-19.93M	$-17.20M	$-13.50M	$-12.39M	$-13.12M	$-19.41M	$-105.51M	$-7.46M	$-16.20M	$-20.53M	$-7.50M	$-6.30M	$-5.66M
Low Forecast	$21.87M	$19.42M	$18.39M	$14.84M	$14.56M	$12.20M	$11.49M	$-1.39M	$1.36M	$2.46M	$-1.33M	$-24.50M	$-14.62M	$-13.03M	$-12.31M	$-22.27M	$-14.77M	$-19.93M	$-17.20M	$-20.25M	$-12.39M	$-13.12M	$-19.41M	$-158.26M	$-7.46M	$-16.20M	$-20.53M	$-11.25M	$-6.30M	$-5.66M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	3.59%	2.58%	0.70%	0.31%	0.31%	0.44%	0.55%	0.86%	0.85%	1.08%	0.47%	0.32%	-0.00%	0.25%	0.54%	1.25%	1.18%	0.13%

Veracyte's average Quarter net income forecast for Mar 21 is $-131.88M, with a range of $-158.26M to $-105.51M. VCYT's average Quarter net income forecast represents a -491014.57% decrease compared to the company's last Quarter net income of $26.86K (Dec 20).

Veracyte SG&A Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	8	7	6	5	5
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	$46.89M	$40.68M	$50.80M	$48.59M	$42.34M	$43.28M	$43.80M	$44.15M	$41.06M	$47.46M	$34.71M	$62.17M	$33.84M	$19.11M	$21.14M	$25.03M	$22.40M	$19.35M
Avg Forecast	$95.76M	$92.51M	$89.94M	$82.18M	$87.24M	$84.30M	$82.73M	$75.45M	$78.61M	$73.98M	$67.55M	$63.05M	$61.96M	$56.83M	$55.95M	$57.32M	$47.99M	$44.54M	$45.66M	$52.11M	$41.93M	$36.22M	$32.24M	$21.91M	$21.60M	$16.02M	$11.45M	$20.02M	$19.83M	$20.16M
High Forecast	$97.97M	$94.65M	$92.01M	$84.07M	$89.25M	$86.24M	$84.63M	$78.93M	$78.92M	$74.29M	$67.55M	$75.66M	$63.39M	$57.72M	$57.24M	$68.79M	$57.59M	$44.54M	$45.66M	$62.53M	$41.93M	$36.22M	$32.24M	$21.91M	$21.60M	$16.02M	$11.45M	$24.03M	$19.83M	$20.16M
Low Forecast	$93.27M	$90.10M	$87.59M	$80.03M	$84.97M	$82.10M	$80.57M	$72.51M	$78.30M	$73.68M	$67.55M	$50.44M	$60.34M	$55.97M	$54.49M	$45.86M	$38.39M	$44.54M	$45.66M	$41.69M	$41.93M	$36.22M	$32.24M	$21.91M	$21.60M	$16.02M	$11.45M	$16.02M	$19.83M	$20.16M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	0.76%	0.72%	0.91%	0.85%	0.88%	0.97%	0.96%	0.85%	0.98%	1.31%	1.08%	2.84%	1.57%	1.19%	1.85%	1.25%	1.13%	0.96%

Veracyte's average Quarter SG&A projection for Mar 24 is $63.05M, based on 1 Wall Street analysts, with a range of $50.44M to $75.66M. The forecast indicates a 34.46% rise compared to VCYT last annual SG&A of $46.89M (Dec 23).

Veracyte EPS Forecast

	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19
# Analysts	4	4	4	4	3	3	3	5	6	3	1	1	1	8	5	4	4	3	4	3	5	4	5	4	5	8	7	6	5	5
EPS	-	-	-	-	-	-	-	-	-	-	-	-	$-0.39	$-0.41	$-0.12	$-0.08	$-0.05	$-0.12	$-0.13	$-0.20	$-0.15	$-0.20	$-0.13	$-0.66	-	$-0.08	$-0.22	$-0.24	$-0.15	$-0.02
Avg Forecast	$0.29	$0.26	$0.24	$0.20	$0.19	$0.16	$0.15	$0.10	$0.12	$0.03	$-0.02	$-0.16	$-0.10	$-0.15	$-0.15	$-0.13	$-0.15	$-0.26	$-0.22	$-0.23	$-0.16	$-0.17	$-0.25	$-0.12	$-0.10	$-0.21	$-0.27	$-0.20	$-0.08	$-0.07
High Forecast	$0.30	$0.26	$0.25	$0.20	$0.20	$0.17	$0.16	$0.15	$0.21	$0.03	$-0.02	$-0.15	$0.03	$-0.12	$-0.15	$-0.13	$-0.15	$-0.26	$-0.22	$-0.23	$-0.16	$-0.17	$-0.25	$-0.12	$-0.10	$-0.21	$-0.27	$-0.20	$-0.08	$-0.07
Low Forecast	$0.28	$0.25	$0.23	$0.19	$0.19	$0.16	$0.15	$-0.02	$0.02	$0.03	$-0.02	$-0.16	$-0.19	$-0.17	$-0.16	$-0.14	$-0.16	$-0.26	$-0.22	$-0.23	$-0.16	$-0.17	$-0.25	$-0.12	$-0.10	$-0.21	$-0.27	$-0.20	$-0.08	$-0.07
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	3.89%	2.80%	0.79%	0.59%	0.35%	0.46%	0.58%	0.86%	0.93%	1.18%	0.52%	5.50%	-0.00%	0.38%	0.83%	1.22%	1.84%	0.20%

According to 4 Wall Street analysts, Veracyte's projected average Quarter EPS for Mar 21 is $-0.12, with a low estimate of $-0.12 and a high estimate of $-0.12. This represents a -26017.92% decrease compared to VCYT previous annual EPS of - (Dec 20).

Veracyte Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
VTYX	Ventyx Biosciences	$1.87	$33.86	1710.70%	Buy
QURE	uniQure	$6.21	$53.67	764.25%	Buy
ENTA	Enanta Pharmaceuticals	$9.53	$65.67	589.09%	Buy
SLDB	Solid Biosciences	$4.85	$17.50	260.82%	Buy
RCKT	Rocket Pharmaceuticals	$13.98	$45.20	223.32%	Buy
FIXX	Q32 Bio	$0.93	$2.70	190.32%	Buy
ANAB	AnaptysBio	$19.00	$52.00	173.68%	Buy
GPCR	Structure Therapeutics	$34.17	$92.40	170.41%	Buy
REPL	Replimune Group	$10.80	$24.20	124.07%	Buy
SNDX	Syndax Pharmaceuticals	$15.83	$34.30	116.68%	Buy
VRDN	Viridian Therapeutics	$20.14	$37.92	88.28%	Buy
KROS	Keros Therapeutics	$56.62	$102.60	81.21%	Buy
IDYA	IDEAYA Biosciences	$26.64	$46.58	74.85%	Buy
CYTK	Cytokinetics	$50.22	$83.23	65.73%	Buy
MRUS	Merus	$46.58	$77.13	65.59%	Buy
KURA	Kura Oncology	$15.92	$26.00	63.32%	Buy
MGTX	MeiraGTx	$6.48	$9.00	38.89%	Buy
CRNX	Crinetics Pharmaceuticals	$54.72	$70.14	28.18%	Buy
PTGX	Protagonist Therapeutics	$41.11	$50.00	21.62%	Buy
RYTM	Rhythm Pharmaceuticals	$56.23	$55.20	-1.83%	Buy
VCYT	Veracyte	$35.94	$35.00	-2.62%	Buy
CERE	Cerevel Therapeutics	$44.96	$33.50	-25.49%	Buy

VCYT Forecast FAQ

Is Veracyte a good buy?

Yes, according to 5 Wall Street analysts, Veracyte (VCYT) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of VCYT's total ratings.

What is VCYT's price target?

Veracyte (VCYT) average price target is $35 with a range of $26 to $44, implying a -2.62% from its last price of $35.94. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Veracyte stock go up soon?

According to Wall Street analysts' prediction for VCYT stock, the company can go down by -2.62% (from the last price of $35.94 to the average price target of $35), up by 22.43% based on the highest stock price target, and down by -27.66% based on the lowest stock price target.

Can Veracyte stock reach $50?

VCYT's average twelve months analyst stock price target of $35 does not support the claim that Veracyte can reach $50 in the near future.

What is Veracyte's current price target trend?

1 Wall Street analyst forecast a $44 price target for Veracyte (VCYT) this month, up 22.43% from its last price of $35.94. Compared to the last 3 and 12 months, the average price target increased by 22.43% and decreased by -2.62%, respectively.

What are Veracyte's analysts' financial forecasts?

Veracyte's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $489.41M (high $503.28M, low $475.2M), average EBITDA is $-70.354M (high $-68.313M, low $-72.348M), average net income is $47.06M (high $52.86M, low $36.86M), average SG&A $329.71M (high $339.06M, low $320.15M), and average EPS is $0.6 (high $0.674, low $0.47). VCYT's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $534.94M (high $547.28M, low $520.99M), average EBITDA is $-76.9M (high $-74.895M, low $-78.674M), average net income is $77.13M (high $79.45M, low $74.52M), average SG&A $360.39M (high $368.7M, low $350.99M), and average EPS is $0.983 (high $1.01, low $0.95).

Did the VCYT's actual financial results beat the analysts' financial forecasts?

Based on Veracyte's last annual report (Dec 2023), the company's revenue was $361.05M, beating the average analysts forecast of $335.18M by 7.72%. Apple's EBITDA was $12.92M, missing the average prediction of $-55.85M by -123.13%. The company's net income was $-74.404M, beating the average estimation of $-49.882M by 49.16%. Apple's SG&A was $184.78M, missing the average forecast of $232.07M by -20.38%. Lastly, the company's EPS was $-1.02, beating the average prediction of $-0.534 by 91.10%. In terms of the last quarterly report (Dec 2023), Veracyte's revenue was $98.2M, beating the average analysts' forecast of $91.97M by 6.77%. The company's EBITDA was $5.03M, missing the average prediction of $-13.221M by -138.04%. Veracyte's net income was $-28.293M, beating the average estimation of $-7.875M by 259.29%. The company's SG&A was $46.89M, missing the average forecast of $61.96M by -24.32%. Lastly, the company's EPS was $-0.39, beating the average prediction of $-0.1 by 288.60%